Clinical Trial Update: Risedronate vs Raloxifene in Hormone Replacement Therapy Discontinuation [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing risedronate and raloxifene for discontinuation of hormone replacement therapy in postmenopausal osteoporosis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Postmenopausal Osteoporosis

Drugs mentioned

• Raloxifene (raloxifene)
• risedronate (risedronate)

Snippet

Sponsor: Sanofi | Conditions: Osteoporosis, Postmenopausal | Phase 4 | Status: TERMINATED